Contrary to data previously reported on in vivo resistant AML cells, we detected a down regulation of antiapoptotic BCL2A1 and BCL2L1, respectively, in in vitro chemoresistant CD34+ cells from our cohort of CR patients (Tables 1 and 3; Figure 1). The gene discussed is BCL2A1; the disease is acute myeloid leukemia.